Dublin, Oct. 06, 2016 -- Research and Markets has announced the addition of the "Exosome Diagnostics and Therapeutics: Global Markets" report to their offering.
"Exosome Diagnostics and Therapeutics: Global Markets" provides an overview of the current state of the exosome industry, existing products on the market and detailed analysis of the competitive environments, including new potential markets for novel products, diagnostics and therapeutics development. The study includes information about significant players in this field of study, trends and obstacles and other information affecting exosome market development.
This report provides:
- An overview of the global markets and related technologies for exosome diagnostics and therapeutics.
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
- Breakdowns of new and exisiting diagnostic methods.
- Evaluation of current therapeutics and those likely to be realized in the near future.
- Analyses of the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Profiles of major players in the industry.
Highlights:
- The global market for exosome diagnostics and therapeutics is projected to grow from $16.1 million in 2016 to $111.8 million in 2021, a five-year compound annual growth rate (CAGR) of 47.3%.
- Diagnostics is the largest sector of the market, expected to grow from $10.0 million in 2016 to $100.0 million in 2021 at a CAGR of 58.5% for the period.
- Therapeutics is expected to grow from $5.0 million in 2016 to $10.0 million in 2021, a CAGR of 14.9%.
Key Topics Covered:
Chapter 1: Introduction
- Study Goals And Objectives
- Reasons For Doing This Study
- Scope And Format
- Methodology And Information Sources
- Intended Audience
- Analyst's Credentials
Chapter 2: Summary
Chapter 3: Introduction To Exosome Market
Chapter 4: Exosome Diagnostics Market
- Market Participants In Exosome-Based Diagnostics Sector
- Evaluation Of Current Diagnostics Sector In Exosome Market
Chapter 5: Exosome Therapeutics Market
- Market Potential For Exosome Therapeutics
- Market Participants In Exosome-Based Therapeutics Sector
Chapter 6: Exosome Reagents And Research Tools Market
- Market Participants For Reagents And Tools For Exosome Research
- Evaluation Of Current Tools And Reagents Sector In Exosome Market
Chapter 7: Patent Analysis Of Exosome Market
Chapter 8: Impact Of Exosome Research On Specific Biopharmaceuticals Markets
Chapter 9: Market Summary
Chapter 10: Select Companies Overview
- Aethlon Medical Inc.
- Exosome Diagnostics Inc.
- Nanosomix Inc.
- System Biosciences (Sbi)
- Thermo Fisher Scientific Inc.
- Ymir Genomics Llc
Chapter 11: List Of The Companies Mentioned In Report
- 101Bio
- Aegle Therapeutics
- Aethlon Medical Inc.
- Amarantus Bioscience Holdings Inc.
- Amsbio LLC
- Bioregenerative Sciences Inc.
- Capricor Therapeutics
- Caris Life Sciences
- Cell Guidance Systems LLC
- Ciloa
- Codiak Biosciences
- Dreirosen Pharma
- Evomic Science LLC
- Excytex
- Exiqon, Inc
- Exocyte Therapeutics Pte Ltd.
- Exosome Diagnostics Inc.
- Exosome Science
- Exosomics Siena Spa
- Exovita Biosciences
- Hansabiomed
- ITH, Immune Therapy Holdings AB
- IZON Science
- JSR Micro Inc.
- Medistem/Intrexon Corp.
- Miltenyi Biotec Gmbh
- Nanosight/Malvern Instruments Ltd.
- Nanosomix Inc.
- New England Peptide Inc.
- Norgen Biotek Corp
- NX Pharmagen
- Orion Pharma Ltd.
- Panacea Pharmaceuticals
- Paradigm Biopharmaceuticals
- Particle Metrix Inc.
- Pfizer
- Promega Corp.
- Qiagen
- Redermis
- Reneuron Group Plc
- Sistemic
- System Biosciences (SBI)
- Therapeutics Solutions International
- Thermofisher Scientific
- YMIR Genomics LLC
For more information about this report visit http://www.researchandmarkets.com/research/fmhx3n/exosome
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diagnostics


Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
First Western Ship Transits Strait of Hormuz Since Iran War Began
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 



